^
    Back
    Association details:
    Biomarker:BCR-ABL1 A337T
    Cancer:Chronic Myeloid Leukemia
    Drug:Scemblix (asciminib) (Bcr-abl tyrosine kinase inhibitor, STAMP inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A2 - Guideline
    Source:
    NCCN
    Published date:
    08/05/2022
    Excerpt:
    Chronic Myeloid Leukemia…The table below lists the BCR::ABL1 kinase domain mutations that should NOT be treated with asciminib…A337T or P465S